Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 12/20 | 0.43 |
| ▸ | F2 | P00734 | 7/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5648186 | 0.85 | KLKB1 (0.45) | KLKB1F2MAP4K1PRSS1 | |
| SCHEMBL5647173 | 0.84 | KLKB1 (0.43) | KLKB1F2MAP4K1PRSS1 | |
| SCHEMBL5651601 | 0.84 | F2 (0.47) | F2ADORA2AADORA1 | |
| SCHEMBL5646766 | 0.83 | F2 (0.55) | KLKB1F2PRSS1 | |
| SCHEMBL5652414 | 0.82 | KLKB1 (0.53) | KLKB1F2PRSS1 | |
| SCHEMBL5647797 | 0.82 | F2 (0.45) | F2PRSS1ADORA2AADORA1 | |
| SCHEMBL5645712 | 0.81 | F2 (0.41) | KLKB1F2MAP4K1PRSS1 | |
| SCHEMBL5969242 | 0.81 | SLC22A12 (0.45) | F2ADORA2AADORA1 | |
| SCHEMBL5647880 | 0.81 | KLKB1 (0.49) | KLKB1F2PRSS1 | |
| SCHEMBL5650326 | 0.81 | F2 (0.41) | KLKB1F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| CN-1918124-A | New pyridin-2-one compounds useful as inhibitors of thrombin | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | CN | disclosed |
| EP-1713774-A1 | NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075424-A1 | NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | PLG, F2, PLAT | KLKB1 113/4885F2 2/4885MAP4K1 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.